--- title: "Organogenesis (NASDAQ:ORGO) Shares Down 3.6% - What's Next?" type: "News" locale: "en" url: "https://longbridge.com/en/news/302941555.md" description: "Organogenesis (NASDAQ:ORGO) shares fell 3.6% on Friday, trading near $0.99 with volume up 64%. Analysts issued mixed views: Weiss Ratings downgraded to 'sell', while Wall Street Zen upgraded from 'strong sell' to 'sell'. Truist Financial cut its price target to $2.00. The stock has an average 'Reduce' rating and a $4.33 target. Recent quarterly earnings missed estimates, reporting a loss of $0.71 per share against expectations of $0.35. Institutional investors like BlackRock and Deutsche Bank increased their stakes in recent quarters." datetime: "2026-10-24T04:20:41.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/302941555.md) - [en](https://longbridge.com/en/news/302941555.md) - [zh-HK](https://longbridge.com/zh-HK/news/302941555.md) generator: "portal-rs" --- # Organogenesis (NASDAQ:ORGO) Shares Down 3.6% - What's Next? Organogenesis (NASDAQ:ORGO - Get Free Report)'s share price dropped 3.6% during trading on Friday. The stock traded as low as $0.9330 and last traded at $0.9932. Approximately 1,338,803 shares were traded during trading, an increase of 64% from the average session volume of 815,558 shares. The stock had previously closed at $1.03. Get **Organogenesis** alerts: ## Analyst Upgrades and Downgrades Several analysts recently weighed in on the stock. Weiss Ratings downgraded shares of Organogenesis from a "sell (d-)" rating to a "sell (e+)" rating in a research report on Monday. Wall Street Zen raised shares of Organogenesis from a "strong sell" rating to a "sell" rating in a research note on Saturday, September 19th. Finally, Truist Financial decreased their target price on shares of Organogenesis from $3.00 to $2.00 and set a "hold" rating for the company in a research report on Friday, August 7th. Two analysts have rated the stock with a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the stock has an average rating of "Reduce" and an average price target of $4.33. **Get Our Latest Stock Report on Organogenesis** ## Organogenesis Stock Down 3.6% The company has a market cap of $127.80 million, a price-to-earnings ratio of -1.15 and a beta of 1.27. The stock has a 50-day simple moving average of $1.45 and a 200-day simple moving average of $2.07. The company has a current ratio of 3.52, a quick ratio of 3.00 and a debt-to-equity ratio of 0.07. Organogenesis (NASDAQ:ORGO - Get Free Report) last posted its quarterly earnings data on Thursday, August 6th. The company reported ($0.71) earnings per share for the quarter, missing the consensus estimate of ($0.35) by ($0.36). Organogenesis had a negative return on equity of 23.89% and a negative net margin of 19.94%. The company had revenue of $43.76 million during the quarter, compared to analyst estimates of $54.27 million. ## Institutional Investors Weigh In On Organogenesis Several hedge funds and other institutional investors have recently added to or reduced their stakes in ORGO. BlackRock Inc. bought a new position in Organogenesis during the 2nd quarter valued at $17,616,000. Deutsche Bank AG acquired a new position in shares of Organogenesis during the 2nd quarter valued at $4,146,000. SG Americas Securities LLC raised its stake in shares of Organogenesis by 39.8% in the 1st quarter. SG Americas Securities LLC now owns 790,766 shares of the company's stock worth $1,874,000 after buying an additional 225,265 shares in the last quarter. Bank of America Corp DE bought a new stake in shares of Organogenesis in the 2nd quarter worth $1,368,000. Finally, Renaissance Technologies LLC raised its stake in shares of Organogenesis by 30.5% in the 1st quarter. Renaissance Technologies LLC now owns 1,068,538 shares of the company's stock worth $2,532,000 after buying an additional 249,838 shares in the last quarter. Institutional investors own 49.57% of the company's stock. ## About Organogenesis (Get Free Report) Organogenesis Holdings Inc NASDAQ: ORGO is a regenerative medicine company that develops, manufactures and commercializes advanced products designed to help repair and restore damaged tissue. Its principal business areas are advanced wound care and surgical and sports medicine, with products intended for use by hospitals, wound-care centers, physicians and other health care providers. The company's advanced wound-care portfolio includes Apligraf, a living cellular skin substitute used in the treatment of certain chronic wounds, as well as Dermagraft, PuraPly and other biologic and synthetic products. ## Read More - Five stocks we like better than Organogenesis - Spotify Soars After Earnings as the Company Touts AI Benefits and Moderating Costs - Lockheed Martin’s Record $292 Billion Backlog Comes With a Delivery Test - Palantir's Next Big Test Isn't a Partnership—It's the Numbers - Kinder Morgan's $4.7 Billion Pipeline Bet Could Be Bigger Than Its Earnings Beat *This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.* ## Should You Invest $1,000 in Organogenesis Right Now? Before you consider Organogenesis, you'll want to hear this. MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Organogenesis wasn't on the list. While Organogenesis currently has a Reduce rating among analysts, top-rated analysts believe these five stocks are better buys. View The Five Stocks Here Continue following MarketBeat Add MarketBeat as your preferred source on Google to see our latest stories in your feed. Add As Preferred Source ### Related Stocks - [ORGO.US](https://longbridge.com/en/quote/ORGO.US.md) - [BAC.US](https://longbridge.com/en/quote/BAC.US.md) - [BLK.US](https://longbridge.com/en/quote/BLK.US.md) - [DB.US](https://longbridge.com/en/quote/DB.US.md) - [TFC.US](https://longbridge.com/en/quote/TFC.US.md) ## Related News & Research - [Organogenesis enters $75 million at-the-market equity sales agreement](https://longbridge.com/en/news/295151249.md) - [Truist Financial Sticks to Its Hold Rating for Organogenesis Holdings (ORGO)](https://longbridge.com/en/news/295734672.md) - [Rocket Lab Earnings Loom: Here’s What Investors Need to Know](https://longbridge.com/en/news/304868682.md) - [Trade Desk Stock Is 90% Below Its High. Can Earnings Turn the Tide?](https://longbridge.com/en/news/304769650.md) - [Citi Downgraded Adobe Stock to Sell. I'd Buy It Now.](https://longbridge.com/en/news/304827167.md) --- > **Disclaimer: This article is for reference only and does not constitute any investment advice.**